Motif Bio said a subsidiary had reached agreement with its former clinical research organisation to settle all obligations without further payment. The pact would result in the reversal of a previously-recognised expense and the reduction of trade payables and accruals by $2.4m. This payable and accrual was shown in the year-end 2018 and interim financials.
Sign up to our
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
UK 350 Risers and Fallers
Tweets not available.